Want to see GB:OBD full AI Analyst Report?
OBD Stock Chart & Stats
0.24 p
0.04 p(3.63%)
At close: 4:00 PM EST
0.24 p
0.04 p(3.63%)
Day’s Range― - ―
52-Week Range0.08 p - 0.75 p
Previous CloseN/A
Volume22.58K
Average Volume (3M)21.87M
Market Cap
£5.36M
Enterprise Value7.45M
Total Cash (Recent Filing)£2.51M
Total Debt (Recent Filing)£4.28M
Price to Earnings (P/E)―
Beta-0.33
Next Earnings
Jan 26, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding4,290,911,000
10 Day Avg. Volume50,883,470
30 Day Avg. Volume21,870,725
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)5.90
Price to Sales (P/S)6.02
P/FCF Ratio-0.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£1.80M
Bulls Say, Bears Say
Bulls Say
Proprietary Platform And Business ModelOxford BioDynamics operates a proprietary chromatin/epigenetic platform (EpiSwitch) that underpins both test commercialization and licensing/collaboration revenue. This platform-driven model supports recurring and scalable income streams across diagnostics and pharma partnerships, a durable structural advantage in precision medicine.
Sustained Revenue GrowthReported double-digit revenue growth indicates commercial traction for tests and services. Consistent top-line expansion validates market demand and can improve bargaining power with partners, enabling follow-on licensing deals and higher test volumes that underpin longer-term revenue durability.
Lean Operating FootprintA small employee base suggests a capital- and labor-light operating model for assay development and lab services. This lean structure can deliver higher operating leverage as volumes scale, allowing incremental revenues to flow more directly to margins if commercialization momentum continues.
Bears Say
High Financial LeverageA debt-to-equity of 4.58 signals significant reliance on borrowings. High leverage constrains strategic flexibility, increases interest and refinancing risk, and magnifies downside if revenue growth slows, making it harder to invest in validation, commercialization, or to absorb setbacks without dilutive financing.
Deteriorating Cash FlowMaterial decline in free cash flow and negative operating cash flow highlight cash consumption despite revenue gains. Persistent cash deficits pressure the balance sheet, increase dependence on external funding, and limit the firm's ability to scale labs, pursue partnerships, or fund regulatory/clinical work without dilutive or costly financing.
Persistent Negative MarginsNegative gross, EBIT and net margins show the company currently cannot cover product costs and operating overhead from revenue alone. Without clear path to positive unit economics or margin improvement, profitability remains uncertain, undermining sustainable cash generation and long-term viability.
Oxford BioDynamics News
OBD FAQ
What was Oxford BioDynamics PLC’s price range in the past 12 months?
Oxford BioDynamics PLC lowest share price was 0.08 p and its highest was 0.75 p in the past 12 months.
What is Oxford BioDynamics PLC’s market cap?
Oxford BioDynamics PLC’s market cap is £5.36M.
When is Oxford BioDynamics PLC’s upcoming earnings report date?
Oxford BioDynamics PLC’s upcoming earnings report date is Jan 26, 2027 which is in 190 days.
How were Oxford BioDynamics PLC’s earnings last quarter?
Oxford BioDynamics PLC released its earnings results on Jun 30, 2026. The company reported -0.001 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.001 p.
Is Oxford BioDynamics PLC overvalued?
According to Wall Street analysts Oxford BioDynamics PLC’s price is currently Overvalued.
Does Oxford BioDynamics PLC pay dividends?
Oxford BioDynamics PLC does not currently pay dividends.
What is Oxford BioDynamics PLC’s EPS estimate?
Oxford BioDynamics PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oxford BioDynamics PLC have?
Oxford BioDynamics PLC has 4,290,911,000 shares outstanding.
What happened to Oxford BioDynamics PLC’s price movement after its last earnings report?
Oxford BioDynamics PLC reported an EPS of -0.001 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -33.333%.
Which hedge fund is a major shareholder of Oxford BioDynamics PLC?
Currently, no hedge funds are holding shares in GB:OBD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oxford BioDynamics PLC
Oxford BioDynamics Plc operates as a biotechnology firm that specializes in identifying and advancing biomarkers, primarily for the pharmaceutical and biotechnology sectors across global markets, including the United States. Its flagship offering is EpiSwitch, an exclusive technological platform employed for discovering, assessing, validating, and tracking epigenetic biomarkers, specifically referred to as chromosome conformation signatures. These are crucial for developing medical diagnostic kits, predicting disease onset, aiding in diagnosis, and informing therapeutic strategies. The company's key products encompass the EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a validated prognostic tool for forecasting patient responses to checkpoint inhibitor immunotherapy; the EpiSwitch CST (Covid Severity Test), a sophisticated blood test designed to predict the severity of COVID-19 in adults; and the EpiSwitch Explorer Array Kit, which enables high-resolution 3D genome analysis and novel biomarker discovery. Established in 2007, Oxford BioDynamics Plc maintains its headquarters in Oxford, United Kingdom.
Technical Analysis
IXICO plc
―
SkinBioTherapeutics
―
Fusion Antibodies Plc
―
Genflow Biosciences Plc
―
Aptamer Group Plc
―